Zydus Cadila announced the launch of its biosimilar Adalimumab, following an approval from the Drug Controller General (India).
According to a press release, the biosimilar was developed by researchers at the Zydus Research Centre. To be marketed under the brand name Exemptia, it will treat autoimmune disorders such as rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, and Ankylosing Spondylitis.
Though it is estimated that more than 12 million patients in India suffer from these chronic conditions which progressively deteriorate and lead to lifelong pain and in some cases, even disability, Adalimumab, the fully human anti-TNF alpha monoclonal antibody, was not available to patients in India.
Zydus has also announced that it will offer a dedicated Exemptia Care support programme to patients and caregivers.
EP News Bureau – Mumbai